Vaccines highly effective against B.1.617.2 Indian variant after 2 doses

Study (5 April to 16 May) found the Pfizer-BioNTech and AstraZeneca vaccines were 88% and 60% effective against symptomatic disease, respectively, after two doses and both were 33% effective after a single dose. There are currently insufficient cases to estimate severe outcomes.

SPS commentary:

Public Health England notes that the difference in effectiveness between the vaccines after two doses may be due to a later rollout of second doses of AstraZeneca than for the Pfizer-BioNTech vaccine. Furthermore, data on antibody profiles show it takes longer to reach maximum effectiveness with the AstraZeneca vaccine.

Public Health England